The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...

The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of ...

The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, along with the aging population and the ongoing rise in risk factors such as hypertension, ...

A painkiller alternative to opioids could be tricking doctors into misdiagnosing heart failure, a new study warns. Drugs like gabapentin and pregabalin are frequently prescribed to treat nerve pain, ...

aBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK Heart failure is a complex clinical syndrome ...

Share on Pinterest A new study raises concerns over long-term melatonin use and cardiovascular risks. Viktoriya Skorikova/Getty Images Researchers say people with insomnia who use melatonin ...

Long-term use of melatonin supplements may be linked with a higher risk of heart failure, according to new research — but does that mean people taking it as a sleep aid should stop using it now? In a ...

Cupid’s got nothing to do with this kind of heartache. A silent epidemic is sweeping the nation, with the number of Americans living with heart failure expected to soar from 6.7 million in 2024 to a ...